Trial: 202105139

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors

Phase

I

Principal Investigator

Waqar, Saiama

Disease Site

Anus; Breast; Colon; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Metastatic Disease; Pancreas; Rectum

Learn more about this study at: clinicaltrials.gov